Sergio Duron
Directeur Général chez Enlaza Therapeutics, Inc.
Fortune : 4 M $ au 30/06/2024
Profil
Sergio G.
Duron is the founder of Anexigen, Inc., Nerio Therapeutics, Inc. He is currently the Chief Executive Officer & Director at Enlaza Therapeutics, Inc., the Managing Partner at Avalon Ventures Management LLC, and the Vice President-Chemistry & Drug Discovery at Sova Pharmaceuticals, Inc. Previously, he worked as the Director-Medicinal Chemistry at Afraxis, Inc., served as a Board Member & Director-Medicinal Chemistry at Zacharon Pharmaceuticals, Inc. from 2010 to 2015, and held the position of Principal at Kalypsys, Inc. and The Scripps Research Institute.
Dr. Duron obtained his doctorate degree from the University of Illinois in 2002 and his undergraduate degree from The University of Texas at Austin in 1995.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
JANUX THERAPEUTICS, INC.
0,18% | 03/06/2024 | 92 630 ( 0,18% ) | 4 M $ | 30/06/2024 |
Postes actifs de Sergio Duron
| Sociétés | Poste | Début |
|---|---|---|
Sova Pharmaceuticals, Inc.
 Sova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sova Pharmaceuticals, Inc. engages in the discovery and development of human therapeutic drugs. It provides internal clinical plan on therapies supported by the mechanism, our preclinical findings, and the development of compounds reported to act on the molecular targets of H2S that include postherpetic neuralgia, chemotherapy induced peripheral neuropathic pain (CIPN pain) and diabetic neuropathy. The company’s pre-clinical findings support large-market indications, such as osteoarthritis, rheumatoid arthritis, neuropathic pain and migraine, that we would seek to develop with a strategic partner. The company was founded by Gary W. Pace and Solomon Snyder in 2010 and is headquartered in La Jolla, CA. | Corporate Officer/Principal | - |
Enlaza Therapeutics, Inc.
 Enlaza Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Enlaza Therapeutics, Inc. is a company that develops novel classes of protein therapeutics using their proprietary war-lock™ platform. The company is based in La Jolla, CA. The company's platform utilizes synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza Therapeutics is pioneering the field of covalent biologics and aims to deliver more efficacious and safer treatments for patients. The CEO of the company is Sergio G. Duron. | Directeur Général | - |
Avalon Ventures Management LLC
 Avalon Ventures Management LLC Investment ManagersFinance Avalon Ventures Management LLC (Avalon Ventures Management) is a venture capital firm founded in 1983 by Kevin J. Kinsella. The firm is headquartered in La Jolla, California. | Private Equity Investor | 01/01/2021 |
Nerio Therapeutics, Inc.
 Nerio Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nerio Therapeutics, Inc. provides biotechnology services. The company is headquartered in La Jolla, CA. | Fondateur | - |
Anciens postes connus de Sergio Duron
| Sociétés | Poste | Fin |
|---|---|---|
Anexigen, Inc.
 Anexigen, Inc. BiotechnologyHealth Technology Anexigen, Inc. is a biotechnology company developing novel methods and compositions to combat existing and burgeoning antimicrobial threats. The company was founded by Sanford Madigan and Sergio Duron and is headquartered in La Jolla, CA. | Fondateur | - |
The Scripps Research Institute
 The Scripps Research Institute Other Consumer ServicesConsumer Services The Scripps Research Institute is a private, non-profit research organizations that performs basic biomedical research in molecular & cellular biology, chemistry, immunology and neuroscience. They receive the majority of its funding from federal agencies such as the National Institutes of Health. The organization also partners with pharmaceutical companies and is affiliated with the Scripps hospital group. The organization was founded in 1955 and is headquartered in La Jolla, California. | Corporate Officer/Principal | - |
Zacharon Pharmaceuticals, Inc.
 Zacharon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Zacharon Pharmaceuticals, Inc. developed small molecular drugs. The company was founded by Jeffrey D. Esko, Charles A. Glass and Brett E. Crawford in 2004 and was headquartered in Novato, CA. | Directeur Technique/Scientifique/R&D | - |
Kalypsys, Inc.
 Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA. | Corporate Officer/Principal | - |
Afraxis, Inc.
 Afraxis, Inc. BiotechnologyHealth Technology Afraxis, Inc. operates as a contract research organization (CRO), specializes in preclinical efficacy evaluations (in vivo and in vitro), neurotoxicity evaluations, and structure-efficacy relationship (SER)-driven medicinal chemistry. It develops Afraxis ESP, an enhanced spine analysis platform that quantifies the morphology and maturity of synaptic dendritic spines, which are fundamental to information processing by neural synapses in the brain. The company was founded by Jay B. Lichter, Carmine Stengone, Susumu Tonegawa and Ben Vollrath in 2007 and is headquartered in San Diego, CA. | Directeur Technique/Scientifique/R&D | - |
Formation de Sergio Duron
| The University of Texas at Austin | Undergraduate Degree |
| University of Illinois | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Kalypsys, Inc.
Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA. | Health Technology |
Afraxis, Inc.
Afraxis, Inc. BiotechnologyHealth Technology Afraxis, Inc. operates as a contract research organization (CRO), specializes in preclinical efficacy evaluations (in vivo and in vitro), neurotoxicity evaluations, and structure-efficacy relationship (SER)-driven medicinal chemistry. It develops Afraxis ESP, an enhanced spine analysis platform that quantifies the morphology and maturity of synaptic dendritic spines, which are fundamental to information processing by neural synapses in the brain. The company was founded by Jay B. Lichter, Carmine Stengone, Susumu Tonegawa and Ben Vollrath in 2007 and is headquartered in San Diego, CA. | Health Technology |
Zacharon Pharmaceuticals, Inc.
Zacharon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Zacharon Pharmaceuticals, Inc. developed small molecular drugs. The company was founded by Jeffrey D. Esko, Charles A. Glass and Brett E. Crawford in 2004 and was headquartered in Novato, CA. | Health Technology |
Avalon Ventures Management LLC
Avalon Ventures Management LLC Investment ManagersFinance Avalon Ventures Management LLC (Avalon Ventures Management) is a venture capital firm founded in 1983 by Kevin J. Kinsella. The firm is headquartered in La Jolla, California. | Finance |
Sova Pharmaceuticals, Inc.
Sova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sova Pharmaceuticals, Inc. engages in the discovery and development of human therapeutic drugs. It provides internal clinical plan on therapies supported by the mechanism, our preclinical findings, and the development of compounds reported to act on the molecular targets of H2S that include postherpetic neuralgia, chemotherapy induced peripheral neuropathic pain (CIPN pain) and diabetic neuropathy. The company’s pre-clinical findings support large-market indications, such as osteoarthritis, rheumatoid arthritis, neuropathic pain and migraine, that we would seek to develop with a strategic partner. The company was founded by Gary W. Pace and Solomon Snyder in 2010 and is headquartered in La Jolla, CA. | Health Technology |
Nerio Therapeutics, Inc.
Nerio Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nerio Therapeutics, Inc. provides biotechnology services. The company is headquartered in La Jolla, CA. | Commercial Services |
Anexigen, Inc.
Anexigen, Inc. BiotechnologyHealth Technology Anexigen, Inc. is a biotechnology company developing novel methods and compositions to combat existing and burgeoning antimicrobial threats. The company was founded by Sanford Madigan and Sergio Duron and is headquartered in La Jolla, CA. | Health Technology |
Enlaza Therapeutics, Inc.
Enlaza Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Enlaza Therapeutics, Inc. is a company that develops novel classes of protein therapeutics using their proprietary war-lock™ platform. The company is based in La Jolla, CA. The company's platform utilizes synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza Therapeutics is pioneering the field of covalent biologics and aims to deliver more efficacious and safer treatments for patients. The CEO of the company is Sergio G. Duron. | Commercial Services |
